Clinical Trial Update: Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot [NA]

View source ↗

Summary

A completed pilot study assessing the feasibility of Iodine-123 IBZM scintigraphy as a diagnostic imaging tool in patients with pheochromocytoma or paragangliom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Iodine-123 IBZM (IBZM)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Chromaffin-tissue Derived Tumors | NA | Status: COMPLETED